Ignite Creation Date:
2024-10-25 @ 7:55 PM
Last Modification Date:
2024-10-26 @ 3:42 PM
Study NCT ID:
NCT06631677
Status:
TEMPORARILY_NOT_AVAILABLE
Last Update Posted:
None
First Post:
2024-09-19
Brief Title:
Compassionate Use of Dupilumab in Adults With Severe Immunoglobulin E IgE-Mediated Food Allergy Who Have Been Previously Treated With Linvoseltamab and Background Dupilumab
Sponsor:
None
Organization:
None
Study Overview
Official Title:
An Open Label Expanded Access Program of Dupilumab in Adults With Severe IgE-Mediated Food Allergy Who Have Been Previously Treated With Linvoseltamab and Background Dupilumab
Status:
TEMPORARILY_NOT_AVAILABLE
Status Verified Date:
2024-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Provide compassionate use of dupilumab in adults with severe IgE-mediated food allergy who have been previously treated with linvoseltamab and background dupilumab
Detailed Description:
Compassionate Use requests are only being considered in response to Individual Patient Investigational New Drug IND applications Availability will depend on location
Study Oversight
Has Oversight DMC:
Is a FDA Regulated Drug?:
Is a FDA Regulated Device?:
Is an Unapproved Device?:
Is a PPSD?:
Is a US Export?:
Is an FDA AA801 Violation?: